Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138546 | Leukemia Research | 2010 | 7 Pages |
Abstract
Small molecules are attractive agents for the treatment of leukemia. We found that a combination of a farnesyltransferase inhibitor, tipifarnib, and an mTOR inhibitor, rapamycin, synergistically inhibited the growth of myeloid leukemia cell lines and primary leukemia cells by inducing apoptosis and cell-cycle blockage. The combined agents reduced the level of phospho-ERK1/2, suggesting that they altered the network of signaling pathways. They also showed synergistic effects in tipifarnib-resistant K562/RR cells. The results support the utility of this combination as a potential therapy for leukemia. The combination might also be effective in overcoming resistance to tipifarnib.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Tadashi Nagai, Ken Ohmine, Shin-ichiro Fujiwara, Mitsuyo Uesawa, Chihiro Sakurai, Keiya Ozawa,